Brief: Algernon Submits Investigational New Drug Application With U.S. FDA For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil For Covid-19
25/05/2020 15:06
May 25 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON SUBMITS INVESTIGATIONAL NEW DRUG (IND)
APPLICATION WITH
U.S. FDA FOR MULTINATIONAL PHASE 2B/3 HUMAN STUDY TO EVALUATE
IFENPRODIL FOR COVID-19
Source text for Eikon: ID:nGNX1xLSBT
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement